Objective:To investigate the effect of methyltransferase like 14 (METTL14) on the proliferation and invasion of breast cancer (BC) cells by regulating cyclin L2 (Cyclin L2, CCNL2) through m6A modification.Methods:Cancer tissues and paracancerous tissues of BC patients in Yantaishan hospital were collected from Aug. 2018 to Feb. 2020. The expression levels of m6A, METTL14 and CCNL2 in tissues were detected by high performance liquid chromatography/mass spectrometry (HPLC/MS) and qRT-PCR. Dual-luciferase reporter assay, qRT-PCR, and western blot were used to verify the regulatory relationship between METTL14 and CCNL2. RIP experiments verified the regulatory relationship between YTH domain-containing family protein (YTHDF2) and CCNL2. Cell viability was detected by MTT method, and cell invasion ability was detected by Transwell.Results:Compared with normal cells (0.24±0.02) and tissues (0.18±0.02) , BC cells MCF-10A (0.47±0.03, t=11.05, P<0.001) and HS-578T (0.41±0.03, t=8.17, P=0.001) and BC tissues (0.39±0.02, t=12.86, P<0.001) m6A level increased. Compared with normal tissues (1.00±0.26) (0.84±0.07) , METTL14 mRNA (1.57±0.28, t=13.50, P<0.001) and protein levels (1.66±0.11, t=10.89, P<0.001) in BC tissues were significantly increased high. Compared with the control group (100.00±10.11) (1.00±0.12) , the BC cell invasion ability (54.15±6.21, t=6.69, P=0.003) and activity (0.64±0.06, t=4.65, P=0.010) were weakened. Compared with the control group (100±11.05) (1±0.13) , the BC cell invasion ability (175.31±13.45, t=7.49, P=0.002) and activity (2.16±0.16, t=9.75, P=0.002) in the METTL14 overexpression group were enhanced, and the effects of METTL14 on cell invasion (137.41±12.64, t=3.56, P=0.024) and activity (1.64±0.15, t=5.59, P=0.005) were partially reversed after m6A inhibitor treatment change. Compared with normal tissues, CCNL2 expression was down-regulated in BC tissues, and the interaction between CCNL2 and METTL14 was confirmed. Compared with the control group (1.00±0.1) (0.64±0.05) , knockdown of METTL14 could make CCNL2 mRNA (1.67±0.05) . 0.13, t=7.08, P=0.002) and protein (1.09±0.09, t=7.57, P=0.002) were up-regulated. METTL14 knockout enhanced the stability of CCNL2 mRNA through a YTHDF2-dependent pathway, compared with sh-METTL14 group (50.47±5.16) (0.52±0.05) , BC cell invasion ability of sh-METTL14+sh-CCNL2 group (71.69±6.41, t=4.47, P=0.011) and activity (0.64±0.05, t=2.94, P=0.042) were improved. Conclusion:METTL14 inhibits the expression of CCNL2 through m6A modification to enhance the invasion and activity of BC cells.

OBJECTIVETo explore the clinical significance of magnetic resonance imaging water-fat separation (Dixon) technique in patients with multiple myeloma.METHODSA total of 41 newly diagnosed patients with multiple myeloma who underwent Dixon in The Affiliated Hospital of Qingdao University from April 2019 to April 2021 were included in this study. Patients were divided into observation group and control group according to whether Dixon performance was normal or not. The differences of clinical data and fat fraction (FF) between the two groups were compared. The correlation between FF and clinical data, disease stages and differences before and after treatment were also compared. The receiver operator characteristic curve of patients was drawn to analyze the diagnostic value of FF combined with serum alkaline phosphatase for bone destruction in patients with multiple myeloma.RESULTSAmong the 41 patients, there were 12 cases in the control group and 29 cases in the observation group. There was no significant difference in age and sex between the two groups. In the observation group, β2-microglobulin concentration and M protein were significantly higher than those in the control group, while serum alkaline phosphatase and FF were lower (P<0.05). In all 41 patients included in the study, there was a significant negative correlation between FF value and β2-microglobulin concentration (r=-0.57), and a significant positive correlation between FF value and serum alkaline phosphatase (r=0.31). After treatment, FF value increased, while myeloma cell percentage, β2-microglobulin concentration and M protein decreased in 11 patients who completed 4 cycles of chemotherapy, and the differences before and after treatment were statistically significant (P<0.05). The value of serum alkaline phosphatase combined with FF value in predicting bone destruction is higher than that of FF value or serum alkaline phosphatase alone.CONCLUSIONDixon's different imaging manifestations can reflect the severity of the disease. FF value is correlated with clinical examination results and R-ISS staging, and there is a significant difference before and after treatment. Serum alkaline phosphatase combined with FF value is better than two indicators alone in predicting bone destruction.

Objective:To investigate the effects of circ_000543 derived from hypoxic exosomes on proliferation and invasion of breast cancer (BC) cells.Methods:Bioinformatic website was used to predict the abnormal expression of circ_000543 in BC tissue and the transcription factor that might regulate circ_000543. Double luciferase report experiment and ChIP assay were used to confirm the regulation relationship between YY1 and circ_000543. Exosomes were separated from normal BC cells and BC cells under hypoxic condition, and qRT-PCR was adopted to detect the expression of circ_000543 in exosomes. The expression of circ_000543 and YY1 in exosomes was intervened and the exosomes were cocultured with BC cells under normoxia. CCK8 and Transwell assay was used to detect the proliferation and invasive ability individually.Results:qRT-PCR experiment found that, compared with MCF-10A cells (1±0.11) and exosomes isolated from normoxic cells (1±0.10), circ_000543 expression was up-regulated in BC cells (1.59±0.13) and exosomes derived from cells under hypoxic condition (1.63±0.12) ( t=6.001, P=0.004; t=6.986, P=0.002). Exosomes derived from cells under hypoxic condition promoted proliferation and invasion of BC cells under normoxia. Inhibition of circ_000543 partially offset the effects of exosomes. YY1 induced the expression of circ_000543 in BC cells as a transcription factor. The expression of circ_000543 was inhibited when YY1 expression was down-regulated; at the same time, down-regulation of YY1 inhibited the effects of exosomes on proliferation and invasion of BC cells. Conclusion:The transcription factor YY1 promoted proliferation and invasion of BC cells by inducing hypoxic breast cancer-derived exosomal circ_000543.

目的:分析浆母细胞淋巴瘤(PBL)患者的临床和病理特征、鉴别诊断、治疗及预后.方法:回顾性分析青岛大学附属医院2013年9月至2020年4月确诊并治疗的7例PBL患者的临床资料,并进行文献复习.结果:7例PBL患者均为HIV阴性,其中男3例,女4例,中位年龄63(51～75)岁.1例为腹股沟淋巴结起病,其余6例为结外器官受累起病,初诊Ann Arbor分期Ⅳ期5例,3例存在B症状.所有患者瘤细胞弥漫表达CD38,其次为CD138和MUM-1,B细胞标志物CD20少见,EBER阳性1例.3例患者接受原发病灶切除术,5例患者以CHOP样方案作为一线化疗方案,其中1例完全缓解并接受自体造血干细胞移植,6例死亡.7例患者中位生存时间7.2(0.8～46.7)个月.结论:PBL侵袭性强,易累及结外组织,多数患者确诊时处于晚期;尚无统一治疗方案,对化疗反应差,死亡率高;有研究报道硼替佐米的应用和自体造血干细胞移植在一定程度上有助于延长患者生存.

目的 探讨慢性淋巴细胞白血病并发隐球菌性脑膜炎的临床特点、诊治方法和经验.方法 报告1例慢性淋巴细胞白血病并发隐球菌性脑膜炎病人,并复习相关文献,总结其病因、临床特点、诊治经过及治疗经验.结果 病人经两性霉素B规范治疗后脑脊液中未再检测到隐球菌,效果显著.结论 慢性淋巴细胞白血病并发隐球菌性脑膜炎较为少见,容易漏诊,病死率极高,早期诊断和积极治疗可获得较好的预后.

急性白血病化疗后发热并肺部阴影多见,若行经验性抗菌治疗效果不好,需行进一步鉴别诊断,明确病原体,做到目标治疗.我科收治1例白血病病人化疗后反复发热,经PCR荧光探针法确诊为肺部结核,经抗结核治疗获得较好疗效.本文报告其临床资料,并结合相关文献介绍白血病合并肺部结核的特点以及PCR荧光探针法诊断的优势.

Objective To explore the clinical effects of subcutaneous injection of bortezomib on multiple myeloma and its side effects. Methods Clinical data of 166 patients with multiple myeloma treated in our hospital between January 2013 and January 2018 were analyzed. Of the patients, 117 cases got subcutaneous injection of bortezomib (SC group), and the other 49 cases got intravenous infusion of bortezomib (Ⅳ group). The curative effects and the incidence of adverse reactions of patients in the two groups were observed and compared. Results After 2 courses of treatment, the percentages of complete remission (CR) cases, of very good partial remission (VGPR) cases and of partial response (PR) cases showed no statistical differences between two groups (P>0.05), and so did they after 4 courses of treatment (P>0.05). Patients in SC group completed 3~18 courses of treatment, 8.5 courses in average, and those in Ⅳ group completed 3~16 courses of treatment, 6.6 courses in average. At the end of the treatment with bortezomib, the percentage of PR in SC group was higher than in Ⅳgroup (P<0.001). No significant difference in PFS and OS were found between two groups (P>0.05). The incidence of all grades of peripheral neuropathy (PN) and the incidence of PN above grade Ⅲ were significantly lower in SC group than in IV group (P<0.05). The incidence of infection was lower in SC group than in IV group (P<0.05). No significant differences were found in other side effects between the two groups (P>0.05). Conclusion The SC injection of bortezomib had comparable early efficacy with Ⅳ injection. It could also reduce the occurrence of PN and improve the drug safety.

目的 探讨血小板减少性疾病病人血小板参数检测的临床意义.方法 应用血细胞分析仪,检测94例原发免疫性血小板减少症(ITP)以及50例急性白血病(AL)、50例再生障碍性贫血(AA)、36例结缔组织病(CTD)导致的继发性血小板减少病人治疗前的血小板参数,包括血小板计数(PLT)、血小板压积(PCT)、血小板分布宽度(PDW)、血小板平均体积(MPV)、大血小板比率(P-LCR),以70例正常人作为对照组.结果 与对照组比较,ITP组、AA组、AL组、CTD组P-LCR升高(F=79.53,P＜0.05);ITP组、CTD组、AA组MPV升高(F=13.21,P＜0.05);ITP组、AA组、AL组、CTD组PLT、PCT降低(F=821.55、670.66,P＜0.05);AA组PDW降低(F=4.87,P＜0.05).与ITP组比较,AA组、AL组、CTD组PLT均升高,PDW、P-LCR均降低;AA组和CTD组PCT降低;AA组和AL组MPV降低(F=4.87～821.55,P＜0.05).与CTD组比较,AA组、AL组的MPV、P-LCR以及AA组PCT均降低(P＜0.05),AA组和AL组血小板参数差异无统计学意义(P＞0.05).ITP病人中完全反应组与部分反应组、无反应组比较,PLT、PCT显著升高,PDW、MPV、P-LCR显著降低,差异有统计学意义(F=6.10～64.90,P＜0.05);与无反应组比较,部分反应组PLT升高,P-LCR降低,差异有统计学意义(P＜0.05),PDW、MPV、PCT差异无显著性(P＞0.05).结论 血小板参数检测有助于血小板减少性疾病的诊断及鉴别诊断,并且可用于评估ITP病人的预后.

OBJECTIVE:To investigate the effects of human umbilical cord blood-derived mesenchymal stem cells(HUCMSC) on the leukemic cell line HL-60 and acute lymphoblastic leukemia cell line Jurkat as well as the role of CXCL12/CXCR4.METHODS:HL-60 cells and Jurkat cells were co-cultured with human umbilical cord blood mesenchymal stem cell (HUCMSC), and the model was treated with G-CSF, AMD3100 and their combination. The cell viability and cell cycle were measured by Cell Counting Kit-8 (CCK-8), the apoptosis and the cell-cycle analysis were assessed by flow cytometry with the Annexin V/PI double staining. The expression of surface CXCR4 protein and total CXCR4 protein of leukemic cells were detected by flow cytometry and Western blot respectively.RESULTS:HUCMSC could decrease the viability of HL-60 cells and Jurkat cells, as well as the percentage of apoptotic cells, they could also increase the number of G0/G1 cells, while G-CSF and AMD3100 could reduce the proliferation of HL-60 cells and Jurkat cells in HUCMSC co-culture model, destructed the anti-apoptotic effect of HUCMSC on HL-60 cells and Jurkat cells, and the combination of 2 drugs resulted in a synergistic effect. The G-CSF could reduce the expression of surface CXCR4 protein and total CXCR4 protein in leukemic cells, while AMD3100 could only decrease the expression of surface CXCR4 protein of leukemia cell membrane, having no effect on the expression of CXCR4 protein in cytoplasm.CONCLUSION:Human umbilical cord blood mesenchymal stem cells can inhibit the proliferation and apoptosis of acute leukemia cells and increase the number of G0/G1 phase cells in leukemic cells. The AMD3100 can decrease the expression of surface CXCR4 protein in leukemia cells, G-CSF can decrease expression of total CXCR4 protein as well as membrane CXCR4 protein. Both of them can block the CXCL12/CXCR4 signal axis, weakening the relationship between leukemia cells and microenvironment. And on the basic of HUCMSC influenced leukemia cells' growth and proliferation, the cell viability will be weakened, its apoptosis will be promoted, and the percentage of G0/G1 phase cells in leukemia cells will be decreased.

Objective To investigate the effect of 5-aza-cytidine on the proliferation of multiple myeloma cell line MM1R and RPMI8226.Methods Human multiple myeloma cell line MM1R and RPMI8226 were cultured to logarithmic growth phase and MM1R resistance was verified.Different concentrations of 5-aza-cytidine were added to co-culture with MM1R and RPMI8226.The proliferation activity of MM1R and RPMI8226 at different time was detected using CCK8,the expression of IFN-γin MM1R and RPMI8226 was measured applying ELISA.Results At the same action time,the proliferative activity of MM1R and RPMI8226 decreased with the increase of concentration of 5-aza-cytidine (F =78.68,63.12;P ＜0.05).Under the same concentration of 5-aza-cytidine,the proliferation of MM1R and RPMI8226 decreased along with the time extending (F =112.12,99.87;P＜0.05).When the action time and the concentration of 5-aza-cytidine were the same,the cell proliferation and inhibition rate (CPIR) of MM1R was higher than that of RPMI8226.When these two cells were treated with different concentrations of 5-aza-cytidine,the IFN-γ expression in the two cells increased with the increase of 5-aza-cytidine concentration (F=46.78,58.67;P＜0.05).Conclusion The 5-aza-cytidine has inhibition action on proliferation of MM1R and RPMI8226 cells in human multiple myeloma,and the inhibitory effect on MM1R was stronger than that on RPMI8226,and at the same time,5-aza-cytidine has a role in promoting the secretion of IFN-γ.

Background: Rituximab had been reported effective on follicular lymphoma. Marginal zone lymphoma and follicular lymphoma both derived from B cell lymphoma. This meta-analysis aimed to evaluate the effectiveness and safety of rituximab treatment in marginal zone lymphoma patients. Methods: Two investigators searched for eligible studies in MEDLINE, Embase and Cochrane Library electronic databases up to November 2015, independently. The patients used rituximab monotherapy were included. We used overall response rate (ORR) and complete response (CR) to evaluate the efficacy of rituximab. Statistical heterogeneity was calculated by using the I-2 P statistic and Cochrane's Q test. We used random-effects models if I-2 > 50% or P < 0.1. Otherwise, we used fixed-effects models. Results: Thirteen studies which included 237 patients were eligible in the meta-analysis. The ORR was 81% (95% CI = 72-88%, 13 studies including 237 patients) and CR rate was 50% (95% CI = 39-61%, 13 studies including 237 patients). As for toxicities, the most frequent nonhematologic toxicity was mild infusion-related symptoms. Conclusions: In this meta-analysis, available evidence suggests that rituximab seems to be a safe and effective therapy for marginal zone lymphoma. Therefore, rituximab provides a good way to treat marginal zone lymphoma.

To establish a method for determining tubeimoside I content in Bolbostemma paniculatum (Maxim.) Franquet; and to investigate the anti-proliferative mechanisms of tubeimoside I on K562 cells. HPLC was employed. Column: RP-C18 (4.6 × 250 mm 5 μm); mobile phase: methanol-water (V:V=68:32); DAD detection wavelength: 214 nm; temperature: room temperature. Effect of tubeimoside I on K562 cell proliferation was determined by MTT assay; and apoptosis rate was measured by flow cytometry. Tubeimoside I exhibited linearity within a 0.408-2.040 mg/mL range (r=0.9996). Average recovery was 98.98% (n=5), with RSD=1.82%. MTT assay showed that treatment with different doses of tubeimoside I for 12 and 24 h could all reduce the viability of K562 cells. Flow cytometry with PI staining revealed that tubeimoside I could induce K562 cell apoptosis within the test concentration range. Compared to the control group, apoptosis was positively correlated with drug concentrations, showing marked dosedependence. The present method is rapid, simple and accurate, which can be used for determining tubeimoside I contents in Bolbostemma paniculatum (Maxim.) Franquet and its preparations. Tubeimoside I has an anti-proliferative effect on K562 cells.

Objective To explore the clinical features and the influence of various prognostic factors on survival of patients with multiple myeloma (MM) and the survival rates of major therapeutic options were evaluated.Methods A retrospective analysis were performed on the clinical characteristics, laboratory examination and therapeutic options of 214 cases of MM patients. Nine clinical and laboratory parameters were analyzed by univariate and multivariate process. Survival analysis about major therapeutic options were performed.Results The median age of onset was 59.7 years. The most common clinical manifestations include bone pain (77.1%), anemia (70%), renal impairment (24.8%). Univariate analysis suggested thatage, percentage of plasma cell in bone marrow, hemoglobin, β2-microglobulin (β2-MG), Scr, stageⅢ were prognostic factors for overall survival (OS). Multivariate analysis suggested that age, percentage of plasma cell in bone marrow, and β2-MG were all independent prognostic factors for OS. Compared with VAD-like regimen, the patients on a BD regimen showed a superior median OS, 56 months and 39 months, respectively, survival curve was significant (P=0.028).Conclusion Clinical manifestations of MM are complicated and difficult to diagnosis. Age, highβ2-MG, high proportion of MM cells were highly related to poor prognosis of MM patients. Compared with traditional VAD regimen, application of new drug bortezomib in patients significantly extend the survival rates of patients.

Graphene oxide (GO) is a hotspot, especially in the field of biomedical. However, the clinical application of GO is still faces a lot of challenges. In order to improve the solubility and biocompatibility of GO, polyethylene glycol (PEG) was grafted on the surface of graphene oxide by amide reaction. PEGylated graphene oxide (PEG-GO) was characterized using Fourier transform infrared spectroscopy (FTIR). The stability of PEG-GO detected in different solutions. Raji cell was selected as a lymphoma cell model to study the cytotoxicity of PEG-GO. Cell viability was detected using the Cell Counting Kit-8 assay. Cells were treated with different concentrations (10-100 μg/mL) of PEG-GO at different time points (6, 12, and 24 h). The FTIR spectrum of PEG-GO indicated that polyethylene glycol was successfully grafted onto GO. PEG-GO had excellent stability in all solutions. Cells treated with PEG-GO (10-100 μg/mL) for 24 hours had survival rates were over 80%. These results demonstrate that PEG-GO had an excellent dispersion in biological solutions and the toxicity of PEG-GO to lymphoma cells was low. The paper may provide cytological evidence for the application of PEG-GO in medicine.

目的 利用斑马鱼的胚胎和幼鱼建立检测药物发育毒性的方法.方法 利用斑马鱼的优势和倒置显微镜、组织切片机等设备建立药物发育毒性检测方法.结果 初步建立了利用斑马鱼胚胎死亡率、胚胎畸形率等进行药物发育毒性研究的方法.结论 本方法为分析药物对胚胎发育的影响提供了一种新的途径,对于药物的合理应用和医药废物的认真处理具有一定的意义,为以后深入研究药物的发育毒性产生机制有一定的帮助.

Objective To compare the efficacy and safety of high-dose dexamethasone(HD-DXM)with conventional prednisone in the treatment of adults with primary immune thrombocytopenia(ITP).Methods A total of 73newly diagnosed ITP patients were divided into two groups in random.Dexamethasone group(DXM group,37patients):oral DXM 40mg/d,to be taken in two doses,for 4days and then discontinued,which was repeated for one more cycle on day 7after the discontinuation.Prednisone group(36patients),oral prednisone 1.0-1.5mg·kg-1·d-1 for 4weeks,and then the dose was gradually decreased to minimum maintenance dose or discontinued.The short-term and long-term efficacy and safety were compared between the two groups.Results For short-term efficacy,after 1-2-week treatment,the response in Dexamethasone group was significantly higher than that in Prednisone group(χ2=7.21,4.30;P<0.05),the efficacy on week 3remained higher,but the difference was not statistically significant(χ2=1.56,P>0.05).For long-term effect,a three-month follow-up showed that,on the first month,the recurrence rate between the two groups was not significant(χ2=0.11,P>0.05),and that on the second and the third month was much lower in Dexamethasone group than that in Prednisone group(χ2=4.49,4.80;P<0.05).In Dexamethasone group,little adverse reactions such as infections or Cushing syndrome were observed;In Prenisone group,Cushing syndrome manifestations were seen in more patients,and some complicated infections were also noted.Conclusion High-dose DXM therapy for ITP is superior than routine-dose Prednisone in terms of short-and long-term efficacy and safety.

近年来,陆续有研究者报道一类特殊的骨髓瘤,其形态表现为淋巴样浆细胞,并有较独特的生物学特点.此型骨髓瘤较为少见,并且因其临床表现、细胞病理学与某些淋巴瘤存在部分相似性,因此不易诊断.现对我院收治的2例患者资料进行回顾性分析,并对相关文献进行复习.

Objective To explore the clinical significance of C-terminal portion of provasopressin(Copeptin),cTnI and Hs-CRP in patients with acute coronary syndrome(ACS). Methods This study consisted of 194 patients who were hospitalized with chest pain.According to coronary angiography(CAG),they were classified into four groups as: CAG normal,unstable angina pectoris(UAP),non-ST elevation myocardial infarction(NSTEMI) and ST elevation myocardial infarction(STEMI).Plasma copeptin,cTnI and Hs-CRP were measured on admission. Results Plasma levels of copeptin,cTnI and Hs-CRP in patients of groups UAP,NSTEMI and STEMI were significantly higher than that in CAG normal group(H=42.57-141.35,P0.05).The levels of copeptin,cTnI and Hs-CRP in patients of groups NSTEMI and STEMI were higher than that in UAP group(H=9.72-107.45,P0.05).The patients with left main coronary stenosis had a higher level of copeptin,cTnI and Hs-CRP than those with a single-,double-or triple-branch coronary stenosis(H=7.26-35.72,P0.05). Conclusion Plasma level of copeptin,cTnI and Hs-CRP is elevated in ACS patients.Copeptin and cTnI,to some extent,may reflect the severity of coronary artery lesion,which is of a clinical value on risk stratification,therapeutic decision-making,and prognostic prediction for patients with ACS.

Objective:To explore the correlation between C-terminal portion of provasopressin(Copeptin) and cardiac troponin I(cTnI) in patients with acute myocardial infarction and the short-term prognosis value of Copeptin. Method:We selected 97 subjects who had acute myocardial infarction(AMI) with onset 24 h in our study,with follow-up average 6 months,and 30 normal coronary angiography(CAG) as control group.The plasma Copeptin were measured by enzyme-linked immunosorbent assay(ELISA);the plasma cTnI were measured by immunofluorometric assay technique.Copeptin and cTnI were measured daily for 3 days.The clinical main adverse cardiac events(MACE) including cardiac death,heart failure,myocardial infarction or recurrent angina pectoris were recorded during hospitalization and follow-up. Result:Compared with control subjects,level of Copeptin and cTnI were higher in patients with AMI(P0.05).The admission plasma levels of Copeptin in AMI were higher than the third day [(17.68 vs 6.46)pmol/L,P0.05],especially the 0~3 h plasma levels of Copeptin were more higher.Negative correlations between Copeptin and cTnI were observed by Spearman correlations analysis.In the AMI patients,Copeptin level was elevated in patients with MACE compared with patients without MACE.Multivariate logistic regression analysis revealed that the third day Copeptin level was independently associated with MACE during average 6 months(odds ratio: 1.315,95% confidence interval: 1.171～1.475,P0.05). Conclusion:There is negative correlation between the level of Copeptin and cTnI of patients with AMI.The third day plasma level of Copeptin is associated with short-term prognosis in patients with AMI.

Objective To understand the bone metabolism, the controlling situation of the bony disease, and their related factors in maintenance hemodialysis (MHD) patients. Methods We investigated renal bone disease in 113 MHD patients in the Hemodialysis Center of the Affiliated Hospital of Qingdao University Medical College, and compared these data with the guidelines of bone metabolism and controlling of bony disease in Kidney Disease Outcome Quality Initiative (K/DOQI) recommended by National Kidney Foundation of the United States. We also analyzed age, gender, Kt/V, body mass index (BMI), years for dialysis, renal function, blood pressure, Hb, and high sensitivity C-reactive protein (hs-CRP) in these patients. Results In the 113 cases, normal serum Ca was found in 61 (54.0%) cases, normal phosphate in 45 (39.8%) cases, normal Ca x P product in 72 (63.7%) cases, and normal iPTH in 35 (31.0%) cases. However, normal values of the above 4 parameters recommended by K/DOQI were only found in 20 (17.7%) cases. Single and multiple variable regression analyses showed that renal osteodystrophy did not correlate with gender, age, hs-CRP, Kt/V, and years for dialysis. However, higher serum creatinine, lower Hb, lower BMI, and blood pressure =140/90mm Hg (1mm Hg=0.133 kPa) were the risk factors for renal osteodystrophy. Among these risk factors, higher serum creatinine, lower Hb and hypertension were the independent risk factors. Conclusion The bone metabolism and the control of the bony disease could not conform to the standards in the K/DOQI guidelines in most hemodialytic patients. The presence of renal osteodystrophy closely relates to higher serum creatinine, lower Hb and hypertension.